Grade @ to @ adverse events occurred in @ % ( @ % CI ; @ % -@ % ) of patients in the ipilimumab plus sargramostim group vs @ % ( @ % CI , @ % -@ % ) of patients in the ipilimumab-alone group ( @-sided P = @ ) .